Mortality involving and not involving COVID-19 among vaccinated vs. unvaccinated in England between Apr 21 and May 23
Author:
Open Access
- 14 February 2026
- journal article
- research article
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 133
Abstract
Background Comparing non-randomized groups, such as COVID-19 vaccinated and unvaccinated, even in the presence of seemingly relevant control variables, is challenging, but in this study, using English data, I show an achievable approach. Methods First, I estimated age-standardized all-cause mortality among vaccinated and unvaccinated ten years and older, covering 26 months from Apr 21 to May 23. Then, I estimated mortality not involving COVID-19, and finally, I contrasted the calculations. Results First, I found that all-cause mortality among unvaccinated was higher than among vaccinated. But, as the pattern was similar concerning mortality not involving COVID-19, the discrepancy can be attributed mainly to unvaccinated having inferior health at the outset. There were nonetheless indications of significant protection for vaccinated between July 21 and Jan 22. In the absence of control variables as a means to compare non-randomized groups, I reached that conclusion by contrasting all-cause mortality with mortality not involving COVID-19. However, while mortality not involving COVID-19 decreased among unvaccinated compared to the first observation month, it remained high among vaccinated, indicating a relative increase. Conclusions An interpretation is that vaccination, despite a potential temporary protection, has increased mortality. Strengthening the interpretation was relatively high mortality among vaccinated not involving COVID-19 counterintuitively following periods of excess mortality. Further strengthening the interpretation was the relatively high mortality not involving COVID-19 among vaccinated, corresponding with excess mortality during much of the same period. Future research should include data over a longer period than those available for this study. Also, future research should examine different age groups, vaccination types, and the number of doses given.Keywords
This publication has 35 references indexed in Scilit:
- Strength and durability of indirect protection against SARS-CoV-2 infection through vaccine and infection-acquired immunityNature Communications, 2025
- COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individualsVaccine, 2024
- Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in NorwayVaccine, 2022
- Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adultsVaccine, 2022
- Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort studyNature Communications, 2022
- Global impact of the first year of COVID-19 vaccination: a mathematical modelling studyThe Lancet Infectious Diseases, 2022
- Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in SwedenThe Lancet, 2022
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataThe Lancet, 2021
- Why Propensity Scores Should Not Be Used for MatchingPolitical Analysis, 2019
- The (mis)use of overlap of confidence intervals to assess effect modificationEuropean Journal of Epidemiology, 2011